Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.
2.
3.

Effect of premedications in a murine model of asparaginase hypersensitivity.

Fernandez CA, Smith C, Karol SE, Ramsey LB, Liu C, Pui CH, Jeha S, Evans WE, Finkelman FD, Relling MV.

J Pharmacol Exp Ther. 2015 Mar;352(3):541-51. doi: 10.1124/jpet.114.220780.

4.

Targeted metabolomic analysis of amino acid response to L-asparaginase in adherent cells.

Purwaha P, Lorenzi PL, Silva LP, Hawke DH, Weinstein JN.

Metabolomics. 2014;10(5):909-919.

5.

HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies.

Fernandez CA, Smith C, Yang W, Daté M, Bashford D, Larsen E, Bowman WP, Liu C, Ramsey LB, Chang T, Turner V, Loh ML, Raetz EA, Winick NJ, Hunger SP, Carroll WL, Onengut-Gumuscu S, Chen WM, Concannon P, Rich SS, Scheet P, Jeha S, Pui CH, Evans WE, Devidas M, Relling MV.

Blood. 2014 Aug 21;124(8):1266-76. doi: 10.1182/blood-2014-03-563742.

6.
7.

Human 60-kDa lysophospholipase contains an N-terminal L-asparaginase domain that is allosterically regulated by L-asparagine.

Karamitros CS, Konrad M.

J Biol Chem. 2014 May 9;289(19):12962-75. doi: 10.1074/jbc.M113.545038.

8.

Hepatomegaly and fever at the time of neutrophil recovery revealing L-asparaginase toxicity in the treatment of acute lymphoblastic leukemia.

Saison J, Berger F, Lebosse F, Audoual R, Thomas X, Michallet M.

Am J Case Rep. 2014 Jan 12;15:13-7. doi: 10.12659/AJCR.889867.

9.

Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.

Timmerman LA, Holton T, Yuneva M, Louie RJ, Padró M, Daemen A, Hu M, Chan DA, Ethier SP, van 't Veer LJ, Polyak K, McCormick F, Gray JW.

Cancer Cell. 2013 Oct 14;24(4):450-65. doi: 10.1016/j.ccr.2013.08.020.

10.

Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.

Salzer WL, Asselin B, Supko JG, Devidas M, Kaiser NA, Plourde P, Winick NJ, Reaman GH, Raetz E, Carroll WL, Hunger SP.

Blood. 2013 Jul 25;122(4):507-14. doi: 10.1182/blood-2013-01-480822.

11.
12.
13.

Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia.

Liu C, Kawedia JD, Cheng C, Pei D, Fernandez CA, Cai X, Crews KR, Kaste SC, Panetta JC, Bowman WP, Jeha S, Sandlund JT, Evans WE, Pui CH, Relling MV.

Leukemia. 2012 Nov;26(11):2303-9. doi: 10.1038/leu.2012.102.

14.

Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift.

Cantor JR, Yoo TH, Dixit A, Iverson BL, Forsthuber TG, Georgiou G.

Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1272-7. doi: 10.1073/pnas.1014739108.

15.

A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity.

Chen SH, Yang W, Fan Y, Stocco G, Crews KR, Yang JJ, Paugh SW, Pui CH, Evans WE, Relling MV.

Leukemia. 2011 Jan;25(1):66-74. doi: 10.1038/leu.2010.256.

16.

Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia.

Panetta JC, Gajjar A, Hijiya N, Hak LJ, Cheng C, Liu W, Pui CH, Relling MV.

Clin Pharmacol Ther. 2009 Dec;86(6):651-8. doi: 10.1038/clpt.2009.162.

17.
18.

Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511.

Wetzler M, Sanford BL, Kurtzberg J, DeOliveira D, Frankel SR, Powell BL, Kolitz JE, Bloomfield CD, Larson RA.

Blood. 2007 May 15;109(10):4164-7.

20.
Items per page

Supplemental Content

Support Center